Sep 04, 2025 • Benzinga
SOMEWHAT-BULLISH
Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed
Company expects to fully repay existing financial debts in 2026 NCX 470 NDA submissions in U.S. ( H1 2026 ) and subsequently in China Milestones payable on U.S. NDA submission and on approval Glaukos extends NCX 1728 research agreement
Sep 02, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Glaukos Builds Dual Growth Engines Amid Market Headwinds
GKOS raises revenue guidance after record 1H sales, fueled by iDose TR adoption and expanding international glaucoma momentum.
Aug 01, 2025 • Motley Fool
SOMEWHAT-BULLISH
Glaukos ( GKOS ) Q2 Revenue Jumps 30%
Glaukos ( NYSE:GKOS ) , a medical technology company focused on novel ophthalmic therapies, announced its financial results for the second quarter on July 30, 2025. The company reported GAAP revenue of $124.1 million, beating analyst expectations of $115.5 million by 7.4%.
Jul 31, 2025 • Zacks Commentary
NEUTRAL
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised
Glaukos' second-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
Jul 30, 2025 • Zacks Commentary
NEUTRAL
Glaukos ( GKOS ) Reports Q2 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of +7.69% and +8.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?